Literature DB >> 27760583

Utilization of Health Services Among Adults With Recurrent Clostridium difficile Infection: A 12-Year Population-Based Study.

Jennifer L Kuntz1, Jennifer M Baker2, Patricia Kipnis2, Sherian Xu Li2, Vincent Liu2, Yang Xie3, Stephen Marcella3, Gabriel J Escobar2.   

Abstract

BACKGROUND Considerable efforts have been dedicated to developing strategies to prevent and treat recurrent Clostridium difficile infection (rCDI); however, evidence of the impact of rCDI on patient healthcare utilization and outcomes is limited. OBJECTIVE To compare healthcare utilization and 1-year mortality among adults who had rCDI, nonrecurrent CDI, or no CDI. METHODS We performed a nested case-control study among adult Kaiser Foundation Health Plan members from September 1, 2001, through December 31, 2013. We identified CDI through the presence of a positive laboratory test result and divided patients into 3 groups: patients with rCDI, defined as CDI in the 14-57 days after initial CDI; patients with nonrecurrent CDI; and patients who never had CDI. We conducted 3 matched comparisons: (1) rCDI vs no CDI; (2) rCDI vs nonrecurrent CDI; (3) nonrecurrent CDI vs no CDI. We followed patients for 1 year and compared healthcare utilization between groups, after matching patients on age, sex, and comorbidity. RESULTS We found that patients with rCDI consistently have substantially higher levels of healthcare utilization in various settings and greater 1-year mortality risk than both patients who had nonrecurrent CDI and patients who never had CDI. CONCLUSIONS Patients who develop an initial CDI are generally characterized by excess underlying, severe illness and utilization. However, patients with rCDI experience even greater adverse consequences of their disease than patients who do not experience rCDI. Our results further support the need for continued emphasis on identifying and using novel approaches to prevent and treat rCDI. Infect Control Hosp Epidemiol. 2016;1-8.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27760583      PMCID: PMC5532139          DOI: 10.1017/ice.2016.232

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  30 in total

1.  A modified poisson regression approach to prospective studies with binary data.

Authors:  Guangyong Zou
Journal:  Am J Epidemiol       Date:  2004-04-01       Impact factor: 4.897

Review 2.  Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system.

Authors:  Eyal Zimlichman; Daniel Henderson; Orly Tamir; Calvin Franz; Peter Song; Cyrus K Yamin; Carol Keohane; Charles R Denham; David W Bates
Journal:  JAMA Intern Med       Date:  2013 Dec 9-23       Impact factor: 21.873

Review 3.  Hospitalization stay and costs attributable to Clostridium difficile infection: a critical review.

Authors:  L Gabriel; A Beriot-Mathiot
Journal:  J Hosp Infect       Date:  2014-05-17       Impact factor: 3.926

4.  Adverse outcomes associated with delayed intensive care unit transfers in an integrated healthcare system.

Authors:  Vincent Liu; Patricia Kipnis; Norman W Rizk; Gabriel J Escobar
Journal:  J Hosp Med       Date:  2011-10-28       Impact factor: 2.960

5.  Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole.

Authors:  Daniel M Musher; Saima Aslam; Nancy Logan; Srikanth Nallacheru; Imran Bhaila; Franziska Borchert; Richard J Hamill
Journal:  Clin Infect Dis       Date:  2005-04-25       Impact factor: 9.079

6.  Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection.

Authors:  Ilan Youngster; George H Russell; Christina Pindar; Tomer Ziv-Baran; Jenny Sauk; Elizabeth L Hohmann
Journal:  JAMA       Date:  2014-11-05       Impact factor: 56.272

7.  Treatment with monoclonal antibodies against Clostridium difficile toxins.

Authors:  Israel Lowy; Deborah C Molrine; Brett A Leav; Barbra M Blair; Roger Baxter; Dale N Gerding; Geoffrey Nichol; William D Thomas; Mark Leney; Susan Sloan; Catherine A Hay; Donna M Ambrosino
Journal:  N Engl J Med       Date:  2010-01-21       Impact factor: 91.245

8.  Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease.

Authors:  Lynne V McFarland; Gary W Elmer; Christina M Surawicz
Journal:  Am J Gastroenterol       Date:  2002-07       Impact factor: 10.864

Review 9.  Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes.

Authors:  Stuart Johnson
Journal:  J Infect       Date:  2009-04-05       Impact factor: 6.072

10.  Using diagnoses to describe populations and predict costs.

Authors:  A S Ash; R P Ellis; G C Pope; J Z Ayanian; D W Bates; H Burstin; L I Iezzoni; E MacKay; W Yu
Journal:  Health Care Financ Rev       Date:  2000
View more
  6 in total

1.  Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Clostridioides difficile Infection and Associated Clinical Outcomes.

Authors:  Erik R Dubberke; Justin T Puckett; Engels N Obi; Sachin Kamal-Bahl; Kaushal Desai; Bruce Stuart; Jalpa A Doshi
Journal:  Open Forum Infect Dis       Date:  2022-09-02       Impact factor: 4.423

2.  Recent Progress for the Effective Prevention and Treatment of Recurrent Clostridium difficile Infection.

Authors:  Isobel Ramsay; Nicholas M Brown; David A Enoch
Journal:  Infect Dis (Auckl)       Date:  2018-03-07

3.  Retrospective analysis of long-term gastrointestinal symptoms after Clostridium difficile infection in a nonelderly cohort.

Authors:  Tamar F Barlam; Rene Soria-Saucedo; Omid Ameli; Howard J Cabral; Warren A Kaplan; Lewis E Kazis
Journal:  PLoS One       Date:  2018-12-17       Impact factor: 3.240

4.  Excess length of hospital stay, mortality and cost attributable to Clostridioides (Clostridium) difficile infection and recurrence: a nationwide analysis in Japan.

Authors:  T Kimura; S Stanhope; T Sugitani
Journal:  Epidemiol Infect       Date:  2020-03-02       Impact factor: 2.451

5.  Antimicrobial susceptibility and molecular characterisation using whole-genome sequencing of Clostridioides difficile collected in 82 hospitals in Japan between 2014 and 2016.

Authors:  Kotaro Aoki; Shinobu Takeda; Takashi Miki; Yoshikazu Ishii; Kazuhiro Tateda
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191

6.  Assessment of Value of Neighborhood Socioeconomic Status in Models That Use Electronic Health Record Data to Predict Health Care Use Rates and Mortality.

Authors:  Alejandro Schuler; Liam O'Súilleabháin; Gina Rinetti-Vargas; Patricia Kipnis; Fernando Barreda; Vincent X Liu; Oleg Sofrygin; Gabriel J Escobar
Journal:  JAMA Netw Open       Date:  2020-10-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.